Lazard Asset Management
IMGN

Lazard Asset Management’s Immunogen Inc IMGN Stock Holding History

Lazard Asset Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,131
Closed -$388K – 2463
2023
Q4 		$388K Sell
13,131
-6,275
-32% -$125K ﹤0.01% 1179
2023
Q3 		$307K Buy
+19,406
New +$323K ﹤0.01% 1266
2023
Q2 		– Sell
-15,232
Closed -$58K – 2602
2023
Q1 		$58K Buy
+15,232
New +$64.9K ﹤0.01% 1750
2022
Q3 		– Sell
-29,389
Closed -$132K – 2602
2022
Q2 		$132K Buy
+29,389
New +$128K ﹤0.01% 1404
2021
Q4 		– Sell
-11,256
Closed -$63K – 2497
2021
Q3 		$63K Buy
+11,256
New +$65K ﹤0.01% 1577
2021
Q2 		– Sell
-5,807
Closed -$47K – 2111
2021
Q1 		$47K Buy
+5,807
New +$47.4K ﹤0.01% 1460
2018
Q3 		– Sell
-73,858
Closed -$718K – 1123
2018
Q2 		$718K Hold
73,858
– – ﹤0.01% 755
2018
Q1 		$776K Buy
73,858
+15,772
+27% +$156K ﹤0.01% 734
2017
Q4 		$372K Buy
+58,086
New +$358K ﹤0.01% 805

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lazard Asset Management's IMGN Position: Q1 2024 in Review

Lazard Asset Management sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 13,131 shares — an estimated $388K sold.

Lazard Asset Management first reported a position in IMGN in Q4 2017 and held it in 9 quarters. The position peaked at $776K in Q1 2018. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Lazard Asset Management reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Lazard Asset Management sold 13,131 Immunogen Inc shares in Q1 2024, an estimated $388K.
  • Lazard Asset Management first reported a position in Immunogen Inc in Q4 2017 and held it in 9 quarters.
  • Lazard Asset Management's Immunogen Inc position peaked at $776K in Q1 2018.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Lazard Asset Management's 13F filing for Q1 2024, filed 14 May 2024.